Taiwan Advance Bio-Pharmaceutical Inc. (4186.TWO)
TWD 15.25
(-3.17%)
TWD 15.25
(-3.17%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 12.6 Million | -20.59 Million | -48.08 Million | -50.32 Million | -150.75 Million |
| Net Income | -11.38 Million | 3.68 Million | -114.44 Million | -83.12 Million | -174.66 Million |
| Depreciation & Amortization | 25.89 Million | 28.18 Million | 30.39 Million | 33.71 Million | 34.7 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -13.45 Million | -52.26 Million | 30.15 Million | 7.09 Million | -36.53 Million |
| Other non-cash items | 14.67 Million | 5.35 Million | 9.01 Million | 12.39 Million | 25.74 Million |
| Investing Cash Flow | -13.69 Million | -8.82 Million | -15.19 Million | -54.44 Million | -29.37 Million |
| Investments in PPE | -11.94 Million | -7.27 Million | -14.2 Million | -55.68 Million | -46.45 Million |
| Acquisitions | 1.4 Million | - | - | - | - |
| Investment purchases | -1.79 Million | -3 Million | - | -505 Thousand | - |
| Sales/Maturities of investments | -5.23 Million | -6.2 Million | -969 Thousand | -3.53 Million | - |
| Other Investing Activities | 3.87 Million | 6.5 Million | 965 Thousand | -1.35 Million | 17.07 Million |
| Financing Cash Flow | 24.67 Million | 28.28 Million | -13.91 Million | 235.4 Million | 216.19 Million |
| Debt repayment | -29.76 Million | -33.06 Million | -9.08 Million | -5.88 Million | -1.17 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 250 Million | 200 Million |
| Other Financing Activities | 49.05 Million | -110 Thousand | 53 Thousand | -160 Thousand | 160 Thousand |
| Accounts receivables | 10 Million | 4.99 Million | -13.59 Million | -9.1 Million | -30.26 Million |
| Accounts payables | 301 Thousand | - | - | - | - |
| Inventory | 2.48 Million | 208 Thousand | -413 Thousand | -385 Thousand | -21 Thousand |
| Other working capital | -26.96 Million | -21.18 Million | 8.8 Million | 16.53 Million | -6.24 Million |
| Cash at beginning of period | 158.55 Million | 159.69 Million | 236.89 Million | 106.25 Million | 70.18 Million |
| Cash at end of period | 182.13 Million | 158.55 Million | 159.69 Million | 236.89 Million | 106.25 Million |
| Capital Expenditure | -11.94 Million | -7.27 Million | -14.2 Million | -55.68 Million | -46.45 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 23.58 Million | -1.13 Million | -77.19 Million | 130.63 Million | 36.06 Million |
| Free Cash Flow | 667 Thousand | -27.87 Million | -62.28 Million | -106 Million | -197.2 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.2 Million | -2.2 Million | 12.9 Million | -11.38 Million | 12.9 Million | -18.25 Million |
| Depreciation & Amortization | 5.15 Million | 5.15 Million | 6.14 Million | 25.89 Million | 6.14 Million | 6.8 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -7.7 Million | -7.7 Million | -2.06 Million | -13.45 Million | -2.06 Million | -5.17 Million |
| Other non-cash items | 2.97 Million | 2.97 Million | 3.03 Million | 14.67 Million | 3.03 Million | 2.89 Million |
| Investing Cash Flow | -8.42 Million | -8.42 Million | -614.5 Thousand | -13.69 Million | -614.5 Thousand | -6.23 Million |
| Investments in PPE | -600.5 Thousand | -600.5 Thousand | -2.42 Million | -11.94 Million | -2.42 Million | -3.54 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -20.35 Million | - | - | -1.79 Million | - | - |
| Sales/Maturities of investments | 5.07 Million | - | - | -5.23 Million | - | - |
| Other Investing Activities | -7.82 Million | -7.82 Million | 1.81 Million | 3.87 Million | 1.81 Million | -2.69 Million |
| Financing Cash Flow | -11.6 Million | -11.6 Million | -10.5 Million | 24.67 Million | -10.5 Million | 22.83 Million |
| Debt repayment | -24.86 Million | - | - | -29.76 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -11.6 Million | -11.6 Million | -10.5 Million | 49.05 Million | -10.5 Million | 22.83 Million |
| Accounts receivables | -13.42 Million | -13.42 Million | 5.84 Million | 10 Million | 5.84 Million | -841 Thousand |
| Accounts payables | -1.09 Million | - | - | - | - | - |
| Inventory | 149.5 Thousand | 149.5 Thousand | 995.5 Thousand | 2.48 Million | 995.5 Thousand | 245.5 Thousand |
| Other working capital | 5.57 Million | 5.57 Million | -8.9 Million | -26.96 Million | -8.9 Million | -4.57 Million |
| Cash at beginning of period | 182.13 Million | - | - | 158.55 Million | - | - |
| Cash at end of period | -21.81 Million | -21.81 Million | 8.9 Million | 182.13 Million | 8.9 Million | 2.88 Million |
| Capital Expenditure | -600.5 Thousand | -600.5 Thousand | -2.42 Million | -11.94 Million | -2.42 Million | -3.54 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -203.95 Million | -21.81 Million | 8.9 Million | 23.58 Million | 8.9 Million | 2.88 Million |
| Free Cash Flow | -2.38 Million | -2.38 Million | 17.59 Million | 667 Thousand | 17.59 Million | -17.26 Million |
INVEST
009160
PBBK
FATBB
JMHLY
DHBK